Anthropic shares early results from six Claude drug-discovery partnerships, starts own rare-disease programs
IAmSamFin · x · 2026-10-28
Anthropic published a blog detailing research partnerships with six organizations using Claude across drug development stages — CAR-T design, antibody lead optimization, regulatory drafting — plus its first in-house drug programs targeting rare childhood diseases. Exec Eric Abrams argues the best way to accelerate cures is running many real drug programs with Claude, since bottlenecks span every stage, not just early molecule design.
More from Companies & People
- Computer scientist on being interviewed by an "AI Reporter": honesty made it fine — fortnow · 2026-10-28
- Google brings Gemini Robotics ER 2 embodied reasoning model to Google Cloud — ZoubinGhahrama1 · 2026-10-28
- Anthropic's $850K multi-agent role tops list of 25 highest-paying open jobs — lennysan · 2026-10-28
- X Launches Photo Resharing With Auto Creator Credit and Revenue Split for Both Parties — Polymarket · 2026-10-28
- Anthropic Enters Drug Discovery a Day After IPO Filing, Sparking Competing-With-Customers Debate — IgorCarron · 2026-10-28
- MIT opens registration for Zero Robotics 2027: code NASA's Astrobee robots on the ISS — RosalindPicard · 2026-10-28